Back to top

vaccines: Archive

Zacks Equity Research

Novavax (NVAX) Starts A New Study on COVID-Flu Combo Jab

Novavax (NVAX) initiates a mid-stage study evaluating its COVID-19-Influenza combination and standalone influenza vaccines in adults aged 50 through 80 years.

PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change BNTXNegative Net Change

Zacks Equity Research

Pfizer (PFE) Pentavalent Meningitis Jab BLA Gets FDA Acceptance

The FDA assigns a standard review to Pfizer's (PFE) BLA for pentavalent meningococcal vaccine candidate (MenABCWY), with a decision expected in October 2023.

SNYNegative Net Change GSKNegative Net Change PFENegative Net Change ABBVNegative Net Change

Zacks Equity Research

Moderna's (MRNA) BA.1 Omicron Booster Gets CHMP Nod for Kids

The CHMP recommends authorizing Moderna's (MRNA) bivalent COVID-19 booster vaccine, targeting the Omicron BA.1 subvariant, for young children aged between six and 11 years.

PFENegative Net Change MRNANegative Net Change KMDANegative Net Change BNTXNegative Net Change

Zacks Equity Research

Icosavax (ICVX) Up 112% on Upbeat Data From RSV Jab Study

Data from an early-stage study showed that Icosavax's (ICVX) investigational RSV vaccine exhibited sustained immunologic response following six months of dose administration.

GSKNegative Net Change PFENegative Net Change BNTXNegative Net Change

Zacks Equity Research

Moderna (MRNA) Up 20% on Upbeat Data From Cancer Jab Study

Data from a mid-stage study showed that Moderna's (MRNA) personalized cancer vaccine candidate combined with Merck's Keytruda reduces the risk of recurrence/death by 44% in melanoma patients.

MRKNegative Net Change MRNANegative Net Change KMDANegative Net Change BNTXNegative Net Change

Andrew Rocco

Trending Today: 5 Stocks in the News

So far this week, several stocks have had headline-driven catalysts. We will cover 5 stocks trending in the news.

AMZNNegative Net Change JPMNegative Net Change MSFTNegative Net Change MRKNegative Net Change AMGNNegative Net Change ORCLNegative Net Change MRNANegative Net Change COUPPositive Net Change GOOGLPositive Net Change BOXNegative Net Change NTNXNegative Net Change RIVNPositive Net Change

Zacks Equity Research

Pfizer (PFE), BNTX's COVID-Flu Combo Jab Gets FDA Fast Track Tag

The FDA grants fast-track designation to Pfizer (PFE)/BioNTech's (BNTX) early-stage combination vaccine candidate, which targets two respiratory diseases - influenza and COVID-19.

PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change BNTXNegative Net Change

Zacks Equity Research

FDA Approves Pfizer, Moderna's Omicron COVID Jabs in Younger Kids

Amid a rise in seasonal respiratory illnesses in younger children across the country, the FDA broadens the label of authorized bivalent Omicron BA.4/BA.5-adapted vaccines to include children as young as six months.

PFENegative Net Change MRNANegative Net Change BNTXNegative Net Change

Zacks Equity Research

Pfizer (PFE) RSV Vaccine Candidate BLA Gets FDA's Priority Tag

The FDA's decision on Pfizer's (PFE) BLA seeking approval for RSV vaccine candidate in older adults is expected in May 2023.

SNYNegative Net Change AZNNegative Net Change GSKNegative Net Change PFENegative Net Change

Zacks Equity Research

Pfizer (PFE) Seeks FDA Nod for Bivalent COVID Jab in Infants

Pfizer (PFE) and partner BioNTech seek label expansion to use their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in young children under five years.

PFENegative Net Change MRKNegative Net Change MRNANegative Net Change BNTXNegative Net Change

Shaun Pruitt

Should Investors Buy Pfizer (PFE) & Moderna (MRNA) Stock for 2023?

Much of the social and economic post-pandemic recovery is accredited to Covid-19 vaccine makers Pfizer (PFE) and Moderna (MRNA). Investors may be wondering if these stocks will continue to be strong investments going into 2023.

PFENegative Net Change MRNANegative Net Change

Derek Lewis

Relative Strength Found Within These 3 Medical Stocks

The Zacks Medical sector has modestly outperformed the S&P 500 over the last three months, up more than 7% vs. the general market's 4% gain.

PFENegative Net Change LLYNegative Net Change ABBVNegative Net Change